RU2762315C2 - Лечение и функциональное излечение вич-инфекции моноклональными антителами к cd4, опосредующими конкурентное ингибирование входа вич - Google Patents

Лечение и функциональное излечение вич-инфекции моноклональными антителами к cd4, опосредующими конкурентное ингибирование входа вич Download PDF

Info

Publication number
RU2762315C2
RU2762315C2 RU2017112967A RU2017112967A RU2762315C2 RU 2762315 C2 RU2762315 C2 RU 2762315C2 RU 2017112967 A RU2017112967 A RU 2017112967A RU 2017112967 A RU2017112967 A RU 2017112967A RU 2762315 C2 RU2762315 C2 RU 2762315C2
Authority
RU
Russia
Prior art keywords
antibody
hiv
cells
subject
mab
Prior art date
Application number
RU2017112967A
Other languages
English (en)
Russian (ru)
Other versions
RU2017112967A (ru
RU2017112967A3 (enExample
Inventor
Чан И ВАН
Original Assignee
Юнайтед Байофарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юнайтед Байофарма, Инк. filed Critical Юнайтед Байофарма, Инк.
Publication of RU2017112967A publication Critical patent/RU2017112967A/ru
Publication of RU2017112967A3 publication Critical patent/RU2017112967A3/ru
Application granted granted Critical
Publication of RU2762315C2 publication Critical patent/RU2762315C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2017112967A 2014-09-16 2014-11-11 Лечение и функциональное излечение вич-инфекции моноклональными антителами к cd4, опосредующими конкурентное ингибирование входа вич RU2762315C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051200P 2014-09-16 2014-09-16
US62/051,200 2014-09-16
PCT/US2014/065048 WO2016043788A1 (en) 2014-09-16 2014-11-11 Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition

Publications (3)

Publication Number Publication Date
RU2017112967A RU2017112967A (ru) 2018-10-17
RU2017112967A3 RU2017112967A3 (enExample) 2018-10-17
RU2762315C2 true RU2762315C2 (ru) 2021-12-17

Family

ID=55533661

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017112967A RU2762315C2 (ru) 2014-09-16 2014-11-11 Лечение и функциональное излечение вич-инфекции моноклональными антителами к cd4, опосредующими конкурентное ингибирование входа вич

Country Status (14)

Country Link
US (1) US11180555B2 (enExample)
EP (1) EP3194442A4 (enExample)
JP (2) JP6716544B2 (enExample)
KR (1) KR20170054478A (enExample)
CN (1) CN107074944B (enExample)
AU (2) AU2014406462A1 (enExample)
BR (1) BR112017005134A2 (enExample)
CA (1) CA2961464A1 (enExample)
MX (1) MX2017003546A (enExample)
RU (1) RU2762315C2 (enExample)
SG (1) SG11201702056YA (enExample)
TW (1) TWI695720B (enExample)
WO (1) WO2016043788A1 (enExample)
ZA (1) ZA201701856B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017003546A (es) * 2014-09-16 2017-08-14 Ubi Ip Holdings Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih.
SG10202100268RA (en) * 2016-08-13 2021-02-25 United Biopharma Inc Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients
SG11202007815TA (en) * 2018-03-05 2020-09-29 Oncoimmune Inc Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
WO2021146272A1 (en) * 2020-01-13 2021-07-22 The Regents Of The University Of California Methods for treating viral infections
CN116063506A (zh) * 2022-09-02 2023-05-05 华道(上海)生物医药有限公司 一种分离的抗体及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211470A1 (en) * 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
RU2250770C2 (ru) * 2002-03-07 2005-04-27 Дзе Китасато Инститьют Лекарственное средство для подавления заражения и пролиферации вируса иммунодефицита человека
US20090060914A1 (en) * 2003-01-15 2009-03-05 Shugene Lynn Deimmunized monoclonal antibodies for protection against hiv exposure and treatment of hiv infection
US20110300069A1 (en) * 2001-12-11 2011-12-08 Biotectid Gmbh Methods of Using Labeled Ligands Having Human CD4 Specificity

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381295A (en) 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
DE3828582A1 (de) 1988-08-23 1990-03-01 Max Planck Gesellschaft Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren
EP0365209A3 (en) 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
JPH0725794B2 (ja) 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
ATE153536T1 (de) 1990-11-27 1997-06-15 Biogen Inc Hiv-induzierte synzytien blockierender anti-cd-4- antikörper
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JPH06125783A (ja) 1991-12-28 1994-05-10 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ抗体およびその調製方法
DE69535002T2 (de) 1994-03-08 2006-12-07 Memorial Sloan-Kettering Cancer Center Rekombinante humanisierte antikörper gegen fb5
US5961976A (en) 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US5962319A (en) 1997-05-19 1999-10-05 Bml, Inc. Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene
JP3231262B2 (ja) 1996-06-05 2001-11-19 株式会社ビー・エム・エル ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体
JPH10155489A (ja) 1996-11-27 1998-06-16 Asahi Chem Ind Co Ltd 組換え抗体及びそれをコードする核酸
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
WO1999061629A1 (fr) 1998-05-25 1999-12-02 Asahi Kasei Kogyo Kabushiki Kaisha Dispositif pour la separation cellulaire et procede de separation
US6090388A (en) 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
CA2299893A1 (en) * 1999-03-02 2000-09-02 Carlos O. Stalgis Hiv therapy
KR100633856B1 (ko) * 2005-07-08 2006-10-13 조통래 산소와 오존을 함유한 미세기포가 녹아 있는 작물의병해충방제제
WO2007094983A2 (en) * 2006-02-03 2007-08-23 Tanox, Inc. Methods and compositions for the inhibition of hiv infection of t cells
WO2008134046A1 (en) * 2007-04-27 2008-11-06 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
MX2017003546A (es) * 2014-09-16 2017-08-14 Ubi Ip Holdings Tratamiento y curacion fucional de la infeccion por vih por anticuerpos monoclonales para cd4, que median la inhibicion competitiva de la entrada de vih.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110300069A1 (en) * 2001-12-11 2011-12-08 Biotectid Gmbh Methods of Using Labeled Ligands Having Human CD4 Specificity
RU2250770C2 (ru) * 2002-03-07 2005-04-27 Дзе Китасато Инститьют Лекарственное средство для подавления заражения и пролиферации вируса иммунодефицита человека
US20030211470A1 (en) * 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
US20090060914A1 (en) * 2003-01-15 2009-03-05 Shugene Lynn Deimmunized monoclonal antibodies for protection against hiv exposure and treatment of hiv infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LU L and et.al., A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains, l. Retrovirology, 2012, N.9, V.104, pp.1-14. *

Also Published As

Publication number Publication date
RU2017112967A (ru) 2018-10-17
JP6716544B2 (ja) 2020-07-01
JP2017529355A (ja) 2017-10-05
TWI695720B (zh) 2020-06-11
ZA201701856B (en) 2020-08-26
CN107074944A (zh) 2017-08-18
JP2020097569A (ja) 2020-06-25
US20170369576A1 (en) 2017-12-28
CN107074944B (zh) 2025-12-05
TW201611845A (en) 2016-04-01
US11180555B2 (en) 2021-11-23
MX2017003546A (es) 2017-08-14
SG11201702056YA (en) 2017-04-27
EP3194442A4 (en) 2018-05-23
KR20170054478A (ko) 2017-05-17
CA2961464A1 (en) 2016-03-24
BR112017005134A2 (pt) 2017-12-12
RU2017112967A3 (enExample) 2018-10-17
AU2021203071A1 (en) 2021-06-17
AU2021203071B2 (en) 2024-11-21
WO2016043788A1 (en) 2016-03-24
AU2014406462A1 (en) 2017-04-06
EP3194442A1 (en) 2017-07-26

Similar Documents

Publication Publication Date Title
US11292839B2 (en) Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients
AU2021203071B2 (en) Treatment and functional cure of HIV infection by monoclonal antibodies to CD4 mediating competitive HIV entry inhibition
TWI735491B (zh) 人類免疫不全病毒中和抗體
JP2023041770A (ja) Ｇｐ１２０ ｖ３グリカン指向性抗体による療法に感受性であるｈｉｖ患者を同定する方法
US20210040185A1 (en) Anti-hiv antibodies
WO2024189628A1 (en) Lag-3 inhibition for enhanced antiviral immune response
EP3762033A1 (en) Anti-hiv antibodies
KR20220121792A (ko) 항-cd30 항체-약물 컨쥬게이트 및 hiv 감염 치료를 위한 이의 용도
HK1236038A1 (en) Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition
EP3010549A1 (en) Pathogen binding agents conjugated to radioisotopes and uses in imaging and therapeutic applications
US20250002565A1 (en) Hiv-binding peptides and medical use thereof
CN105980405A (zh) Hiv抗原和抗体及其组合物、方法和用途
HK40003703A (en) Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients
Cheeseman Antibody effector functions critical to mucosal protection against HIV-1

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190812

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20200915

HZ9A Changing address for correspondence with an applicant